drug · antibody
cetrelimab
Phase 2updated 3mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 10 investigational indications.
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
Trials studying cetrelimab
- phase2A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- phase2Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- phase2A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- phase3A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- phase3A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- phase1A Study of JNJ-1761981 in Participants With Solid Tumors
- phase1A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- phase1A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
News(1)
- Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBCA biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.onclive · 3mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that